Ticker: MTN

Vail Resorts

Consumer Consumer Discretionary Gambling, Resorts & Casinos
Price 145.72
Reco Hold Potential 64 Risk 42 Updated 2026-07-27

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell
Description

Company and Business Model

Vail Resorts operates in the consumer discretionary sector, primarily focusing on mountain resort operations. Its core products include ski resorts, lodging, and related services. Major business segments encompass lift ticket sales, ski school, dining, and retail operations. The company generates revenue mainly from lift ticket sales and accommodations, supplemented by food and beverage services.

Investment Profile

The investment profile of Vail Resorts may appeal more to dividend investors due to its notable dividend yield. However, the stock's high volatility and risk factors suggest a cautious approach. It may not be ideal for growth or value investors seeking stability.

Fundamental metrics (experimental) Updated: 2026-07-27
EPS (TTM) — earnings per share for the last 12 months, $
4.33
Revenue QoQ — quarter-over-quarter revenue growth
11.2%
EPS surprise
-1.5%
20d volatility
1.3%
Dividend yield
6.0%
last ex-date
2026-06-25
AI recommendation changes
Date Before After Reason
2026-07-23 Buy Hold Mixed performance; cautious outlook amid market uncertainty.
2026-07-09 Hold Buy Solid fundamentals, but mixed momentum signals present uncertainty.
2026-07-02 Buy Hold Stable dividend, mixed momentum, moderate growth outlook.
Analyst forecasts
Date Analyst Action Target Price Then
2026-06-09 Truist Financial Target Lowered 212 → 195 129.705
2026-06-09 Stifel Nicolaus Target Lowered 172 → 167 137.21
2026-06-09 Mizuho Securities Target Lowered 191 → 174 137.21
News Page 1 of 1
Micron J.M. Smucker GSK Alibaba Vail Resorts Qualcomm

Stocks to Watch: Nuvalent Soars on GSK Acquisition Announcement, J.M. Smucker Reports Strong Earnings, SailPoint Issues Weak Guidance

Nuvalent's shares surged nearly 39% following GSK's announcement of a $10.6 billion acquisition, highlighting significant market activity in the pharmaceutical sector. Meanwhile, J.M. Smucker's strong earnings report positively impacted its stock, while SailPoint's disappointing guidance led to a notable decline in its shares.